BME vs CARE

The Advanced Deterministic Scorecard reveals a Piotroski F-Score of 5/9, indicating stable but not strong financial health, while the absence of an Altman Z-Score prevents a full bankruptcy risk assessment. Despite a high dividend yield of 7.43%, the unsustainable 162.83% payout ratio raises concerns about dividend continuity. Profitability metrics show mixed signals with a 100% gross margin but zero profit margin and negative ROE of -4.63%, suggesting underlying operational inefficiencies. The technical trend score of 10/100 indicates strong bearish momentum, further weakening the investment case.

CARE is currently trading at a fair valuation, with a current price of $24.37 closely aligned with its Graham Number ($24.29) and Intrinsic Value ($22.49). The Piotroski F-Score of 4/9 indicates stable but mediocre financial health, while the technical trend is heavily bearish (10/100), suggesting the stock may be overextended following a massive 59.6% one-year rally. While the forward P/E of 9.75 is attractive and Q/Q revenue growth is strong at 15%, the lack of dividend yield and low ROA (0.66%) limit the bullish case.